Research Topics
Species | Gerald KruegerSummaryAffiliation: University of Utah Country: USA Publications
| Collaborators
|
Detail Information
Publications
A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasisGerald G Krueger
Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT 84132 2409, USA
J Dermatolog Treat 19:146-55. 2008..To evaluate the safety and efficacy of multiple courses of alefacept in combination with traditional psoriasis therapy for the treatment of chronic plaque psoriasis (CPP)...- Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitisGerald G Krueger
University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
J Drugs Dermatol 6:185-93. 2007..To characterize the pharmacokinetics of tacrolimus after topical application in adult and pediatric patients with moderate to severe atopic dermatitis from all clinical trials in which tacrolimus blood levels were obtained... - Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trialGerald G Krueger
University of Utah Health Sciences Center, Salt Lake City, Utah 84132 0001, USA
J Am Acad Dermatol 54:S112-9. 2006..Etanercept provides rapid, significant improvement in psoriatic symptoms and disease... - Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trialG G Krueger
Department of Dermatology, University of Utah Health Sciences Center, 30 N 1900 E, Salt Lake City, UT 84132 0001, USA
Br J Dermatol 153:1192-9. 2005..Etanercept, a soluble tumour necrosis factor receptor, lessens the severity of psoriasis as measured by physician-reported clinical outcomes. Equally important is the patient perspective on the effect of etanercept therapy on daily life... - Psoriasis--recent advances in understanding its pathogenesis and treatmentGerald Krueger
Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA
J Am Acad Dermatol 53:S94-100. 2005..The advent of new, cosmetically attractive vehicles may enhance compliance, add to the use of topical agents, and potentially improve patient outcomes... - The remittive effects of alefaceptGerald G Krueger
Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
J Cutan Med Surg 8:10-3. 2004..Alefacept is a remittive therapy for psoriasis... - Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritisGerald Krueger
University of Utah School of Medicine, Department of Dermatology, Salt Lake City, UT 84132, USA
Arch Dermatol 140:218-25. 2004..To summarize the role of tumor necrosis factor (TNF) in the pathogenesis of psoriasis and psoriatic arthritis (PsA) and to present the latest data on the efficacy of TNF inhibitors in these diseases... - Efficacy of acitretin and commercial tanning bed therapy for psoriasisChristopher S Carlin
Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, 84132, USA
Arch Dermatol 139:436-42. 2003..To assess the efficacy of acitretin and commercial tanning bed therapy for the treatment of moderate to severe chronic plaque-type psoriasis... - A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisGerald G Krueger
University of Utah Health Sciences Center, Salt Lake City, USA
J Am Acad Dermatol 47:821-33. 2002..In previous phase II studies, alefacept significantly improved psoriasis and was well tolerated. The clinical response to alefacept was durable... - Fibroblasts and dermal gene therapy: a minireviewG G Krueger
Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA
Hum Gene Ther 11:2289-96. 2000..Although moving GMFb to an in vivo setting is an invasive procedure, there are a number of clinical settings where GMFb appear to be the suitable cell for gene therapy... - Alefacept: a novel biologic in the treatment of psoriasisClive M Liu
Department of Dermatology, University of Utah, 30 North 1900 East #4B454, Salt Lake City, UT 84132, USA
Drugs Today (Barc) 40:961-74. 2004..This selective effect on the immune system distinguishes alefacept from immunosuppressive therapies that are nonselective... - Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeksGerald D Weinstein
University of California, Irvine, USA
J Am Acad Dermatol 48:760-7. 2003..Tazarotene cream 0.1% was generally more effective, although slightly less well tolerated, than the 0.05% cream... - Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathwaysRajan P Nair
Department of Dermatology, University of Michigan, Ann Arbor, Michigan 48109, USA
Nat Genet 41:199-204. 2009..Our results expand the catalog of genetic loci implicated in psoriasis susceptibility and suggest priority targets for study in other auto-immune disorders... - An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapyBernard Goffe
Dermatolog Associates, Seattle, Washington 98101, USA
Clin Ther 27:1912-21. 2005..Information on longer-term safety and tolerability is needed to confidently prescribe alefacept therapy for chronic plaque psoriasis beyond 1 or 2 courses... - A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasisMark Lebwohl
Departments of Dermatology, Mount Sinai Medical Center, New York, NY 10029 6574, USA
Int J Dermatol 41:269-74. 2002..A clobetasol propionate foam product is as effective as clobetasol propionate solution in the treatment of scalp psoriasis... - Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Kim A Papp
Probity Medical Research, Waterloo and University of Western Ontario, London, ON, Canada
Lancet 371:1675-84. 2008..This study assessed the efficacy and safety of ustekinumab in psoriasis patients and assessed dosing intensification in partial responders... - Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled studyBruce E Strober
Department of Dermatology, New York University Medical Center, 550 First Ave, TCH 158, New York, NY 10016, USA
Arch Dermatol 145:1262-6. 2009..To assess the efficacy of alefacept for the treatment of severe alopecia areata (AA)... - A human interleukin-12/23 monoclonal antibody for the treatment of psoriasisGerald G Krueger
University of Utah, Salt Lake City, USA
N Engl J Med 356:580-92. 2007..Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 monoclonal antibody in treating psoriasis... - Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasisGerald G Krueger
Department of Dermatology, University of Utah Health Sciences Center, 50 N Medical Drive, Suite 4B 454, Salt Lake City, UT 84132, USA
Expert Opin Biol Ther 2:431-41. 2002..Alefacept did not alter the primary or acquired immune response in psoriatic patients. Clinical data obtained to date support the use of alefacept as a safe and remittive therapy for psoriasis... - Association between IL13 polymorphisms and psoriatic arthritis is modified by smokingKristina Callis Duffin
Department of Dermatology, University of Utah School of Medicine, 30 North 1900 East, Salt Lake City, Utah 84132, USA
J Invest Dermatol 129:2777-83. 2009..88, P=0.74, CC/non-smoker, prevalence 42% (reference), CC/smoker prevalence 47%, OR 1.21, P=0.47). This study suggests that IL13 polymorphisms associate most strongly with PsA and that smoking may modulate this effect... - Impact of obesity and smoking on psoriasis presentation and managementMark D Herron
Department of Dermatology, University of Utah School of Medicine, Health Sciences Center, 30 North 1900 East, Salt Lake City, UT 84132, USA
Arch Dermatol 141:1527-34. 2005.... - Current concepts and review of alefacept in the treatment of psoriasisGerald G Krueger
Department of Dermatology, 4B454 School Medicine, University of Utah Health Sciences Center, 30 N 1900 E, Salt Lake City, UT 84132 2409, USA
Dermatol Clin 22:407-26, viii. 2004.... - Genetic variations in cytokines and cytokine receptors associated with psoriasis found by genome-wide associationKristina Callis Duffin
Department of Dermatology, School of Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah 84132 2409, USA
J Invest Dermatol 129:827-33. 2009..These discoveries pose the challenge of elucidating the role of common genetic variants in susceptibility to and manifestations of psoriasis... - Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasisKristina Callis Duffin
Department of Dermatology, University of Utah, Salt Lake City, Utah 84132, USA
J Am Acad Dermatol 60:604-8. 2009..We sought to determine what clinical features of psoriasis predict sleep interference... - Seborrheic keratoses: a study comparing the standard cryosurgery with topical calcipotriene, topical tazarotene, and topical imiquimodMark D Herron
University of Utah, Department of Dermatology, School of Medicine, Salt Lake City, UT, USA
Int J Dermatol 43:300-2. 2004..Patients with seborrheic keratoses frequently desire an effective topical therapy for seborrheic keratoses... - The effect of hair color on the incorporation of codeine into human hairDouglas E Rollins
Department of Pharmacology and Toxicology University of Utah Health Sciences Center, Salt Lake City, Utah 84112, USA
J Anal Toxicol 27:545-51. 2003..The incorporation of these drugs into hair should be studied carefully in humans to ensure the appropriate interpretation of drug concentrations... - Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide associationKristina Callis Duffin
4A330 School of Medicine, Salt Lake City, UT 84132, USA
Dermatol Ther 23:101-13. 2010..Many of these genetic variations also associate with immune disorders considered psoriatic co-morbidities, including Crohn's disease and diabetes... - Obesity in early adulthood as a risk factor for psoriatic arthritisRazieh Soltani-Arabshahi
Department of Dermatology, University of Utah School of Medicine, 30 North 1900 East, Salt Lake City, UT 84132, USA
Arch Dermatol 146:721-6. 2010..To study whether obesity increases the risk of psoriatic arthritis (PsA), given that obesity is a risk factor for psoriasis and is associated with more severe disease... - Genome-wide association analysis identifies three psoriasis susceptibility lociPhilip E Stuart
Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA
Nat Genet 42:1000-4. 2010..We also replicated a recently identified association signal near RNF114 (rs495337, combined P = 2 × 10??)... - Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritisArthur Kavanaugh
Division of Rheumatology, Allergy and Immunology, University of California at San Diego, 9500 Gilman Drive, San Diego, CA 92093, USA
J Rheumatol 33:2254-9. 2006..To examine the effect of infliximab on employment status, time lost from work, and productivity in a double-blind, placebo-controlled study of patients with active psoriatic arthritis (PsA)... - Psoriasis options abound. Ongoing research on Enbrel and Raptiva supports their use in psoriasis treatmentGerald G Krueger
Health News 10:10-1. 2004 - A randomized trial of etanercept as monotherapy for psoriasisAlice B Gottlieb
Clinical Research Center, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, 08901 0019, USA
Arch Dermatol 139:1627-32; discussion 1632. 2003..To determine safety and efficacy of monotherapy with etanercept... - Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trialSteven R Feldman
Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1071, USA
J Am Acad Dermatol 53:887-9. 2005..At week 12, improvement in Dermatology Life Quality Index was 47% to 61% with etanercept compared with 11% with placebo (P < .0001). Etanercept rapidly and substantially improved patients' health-related quality of life... - Development and use of alefacept to treat psoriasisGerald G Krueger
Department of Dermatology, University of Utah Health Sciences Center, 4B454 School of Medicine, 30 N 1900 E, Salt Lake City, UT 84132-2409, USA
J Am Acad Dermatol 49:S87-97. 2003..Adverse events in the placebo and active treatment arms did not differ. We conclude that alefacept significantly improves psoriasis and produces durable clinical improvement with a very favorable safety profile... - A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment of photodamageSewon Kang
University of Michigan Medical Center, Department of Dermatology, Ann Arbor, Michigan 48109 0314, USA
J Am Acad Dermatol 52:268-74. 2005..Previous studies indicate that tazarotene is efficacious in reducing signs of photodamage. Objective We sought to confirm the efficacy and tolerability of tazarotene 0.1% cream in the treatment of facial photodamage... - National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screeningAlexa B Kimball
Department of Dermatology, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts 02114, USA
J Am Acad Dermatol 58:1031-42. 2008.... - Keratoderma blennorrhagicumScott R Florell
N Engl J Med 349:2367-8. 2003 - A role for epigenetics in psoriasis: methylated Cytosine-Guanine sites differentiate lesional from nonlesional skin and from normal skinJohann E Gudjonsson
Department of Dermatology, University of Michigan, Ann Arbor, Michigan 48109, USA
J Invest Dermatol 132:506-8. 2012..In this issue, Roberson et al. demonstrate that lesional skin in psoriasis is accompanied by changes in DNA methylation, which revert back to baseline with treatment, indicating that DNA methylation in psoriasis is dynamic... - A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisChristopher S Carlin
Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, Utah 84132, USA
J Am Acad Dermatol 50:859-66. 2004..We conclude that PASI 50 equates to a clinically meaningful improvement in psoriasis and represents a discerning primary endpoint... - Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque psoriasis, and their associated phenotypesTanya E Christensen
Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah 84132-2409, USA
J Invest Dermatol 126:2397-403. 2006.... - Multiple Loci within the major histocompatibility complex confer risk of psoriasisBing Jian Feng
Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT, USA
PLoS Genet 5:e1000606. 2009..These results demonstrate that there are at least two additional loci within the MHC conferring risk of psoriasis... - Genetics of psoriasis and psoriatic arthritis: update and future directionKristina Callis Duffin
Department of Dermatology, University of Utah, Salt Lake City, Utah, USA
J Rheumatol 35:1449-53. 2008..This article is a summary of that presentation and a review of the literature... - An analysis of select pathogenic messages in lesional and non-lesional psoriatic skin using non-invasive tape harvestingNicholas R Benson
DermTech International, La Jolla, California 92037, USA
J Invest Dermatol 126:2234-41. 2006..Data demonstrate that tape stripping reveals mRNA markers not detected in biopsy samples and thus the method may be a useful supplement to biopsy... - Consensus on a core set of domains for psoriatic arthritisDafna D Gladman
J Rheumatol 34:1167-70. 2007..quot;.. - Induction of dramatic hyperpigmentation in a patient with generalized lichen planus treated with re-PUVAChristopher S Carlin
Department of Dermatology, University of Utah, 50 North Medical Drive, Salt Lake City, UT 84132, USA
J Cutan Med Surg 6:125-7. 2002.... - From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasisMark Lebwohl
Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA
J Am Acad Dermatol 58:94-105. 2008..Biologics are widely used in the treatment of psoriasis and psoriatic arthritis... - A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approachBruce Strober
Department of Dermatology, New York University Medical Center, New York, NY, USA
J Am Acad Dermatol 61:S1-S46. 2009..The final rankings and analysis provide guidance for practical, safe, and efficacious treatment options in a number of complex psoriasis scenarios... - AAD consensus statement on psoriasis therapiesJeffrey P Callen
J Am Acad Dermatol 49:897-9. 2003 - A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genesMichele Cargill
Celera, Alameda, CA 94502, USA
Am J Hum Genet 80:273-90. 2007..These data, and the previous observation that administration of an antibody specific for the IL-12p40 subunit to patients with psoriasis is highly efficacious, suggest that these genes play a fundamental role in psoriasis pathogenesis... - Clinical features of psoriatic arthritisGerald G Krueger
Am J Manag Care 8:S160-70. 2002..The development of TNF inhibitors directed specifically at the mechanisms of skin and joint inflammation offers hope to patients who suffer from the debilitating effects of PsA... - Doxycycline-inducible retroviral expression of green fluorescent protein in immortalized human keratinocytesPritmohinder S Gill
Division of Nephrology and Hypertension, University of Utah Health Science Center and Salt Lake Veterans Affairs Medical Center, Salt Lake City, UT 84132, USA
Exp Dermatol 11:266-74. 2002..Our observations demonstrate an efficient method for achieving stable Dox-regulatable transgene expression in human keratinocytes... - Outcome measures in psoriatic arthritisDafna D Gladman
The University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada
J Rheumatol 34:1159-66. 2007..This article summarizes these features of PsA as well as current knowledge on the instruments available for the assessment of these domains... - FGF-7 expression enhances the performance of bioengineered skinGulsun Erdag
Center for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School and Shriners Hospital for Children, Boston, MA 02114, USA
Mol Ther 10:76-85. 2004..These results demonstrate that genetic modification can be used to enhance performance and that expression of FGF-7 augments several properties important to the wound-healing properties of bioengineered skin... - The 5q31 variants associated with psoriasis and Crohn's disease are distinctYonghong Li
Celera, 1401 Harbor Bay Parkway, Alameda, CA 94502, USA
Hum Mol Genet 17:2978-85. 2008..These results identify the most significant 5q31 risk variants for psoriasis and suggest that distinct 5q31 variants contribute to CD and psoriasis risk...